Recruiting

Custom immune cells targeting advanced solid tumors

Plain-English translation of NCT07523529 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This study is testing a new type of cancer treatment called autologous dual-target CAR-T cells. Researchers take your own immune cells, reprogram them in the laboratory to recognize and attack cancer cells that have two specific proteins on their surface, and then infuse the modified cells back into your body. The goal is to help your immune system fight cancers that have spread or are resistant to standard therapies.

Many patients with advanced solid tumors run out of effective treatment options when standard chemotherapy and surgery stop working. This treatment aims to harness the body's own immune system in a more targeted way by customizing immune cells to match each patient's individual cancer.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with advanced, unresectable, or metastatic solid cancer (including certain brain tumors) that has not responded to standard treatment or for which standard treatment is not available
your tumor contains at least one qualifying pair of target proteins at detectable levels
you have adequate organ function and overall health to safely undergo the treatment
you have at least one measurable tumor that can be tracked during the study

You likely don't qualify if…

you have an active, uncontrolled infection (including tuberculosis, HIV, hepatitis B or C with high viral levels)
you are currently taking high-dose steroids or other strong immunosuppressive medications
you have active uncontrolled autoimmune disease requiring ongoing immunosuppression
you have significant heart, lung, or other major medical problems that would make this treatment unsafe
you have received a similar gene-modified cell therapy targeting the same proteins within the past 6 months

What participation looks like

First, doctors will review a sample of your tumor to identify which proteins are present and confirm you qualify. If you qualify, you will undergo chemotherapy to prepare your body, then have immune cells collected through a procedure called leukapheresis. These cells will be sent to a lab to be reprogrammed and grown over several weeks. Once ready, you will receive an infusion of your modified cells back into your body. You will be monitored closely in the hospital and during follow-up visits for at least 2 years, with long-term safety monitoring continuing for up to 15 years.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Trial locations(1 site)

China

Peking University Shenzhen Hospital, Shenzhen, Guangdong